Glaukos

GKOS · NYSE

$173.43+$6.47 (+3.88%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $166.96

GKOS analyst rating

BuyConsensus of 14 analysts over the last 12 months. 86% rate it a buy.

Strong buy0
Buy12
Hold2
Underperform0
Sell0

12-month price target · 15 analysts

Average $201.79 (+16.4% upside)

Low: $173.72
Now: $173.43
High: $236.25

Upgrades and downgrades

The latest rating actions, newest first

GKOS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Oct 12, 2026	Maintains	Buy	$202.00 → $205.00	48%
Jefferies	Sep 22, 2026	Maintains	Buy	$190.00 → $210.00	40%
BTIG	Aug 20, 2026	Maintains	Buy	$193.00 → $202.00	48%
UBS	Jul 30, 2026	Maintains	Neutral	$150.00 → $172.00	43%
HC Wainwright & Co.	Jul 30, 2026	Maintains	Buy	$168.00 → $195.00	40%
Citigroup	Jul 30, 2026	Maintains	Buy	$175.00 → $188.00	60%
Piper Sandler	Jul 30, 2026	Maintains	Overweight	$165.00 → $195.00	51%
Jefferies	Jul 30, 2026	Maintains	Buy	$165.00 → $190.00	40%
Stifel	Jul 30, 2026	Maintains	Buy	$175.00 → $190.00	40%
Truist Securities	Jul 30, 2026	Maintains	Buy	$180.00 → $215.00	50%

The case for and against

Updated Oct 14, 2026

Bull case

Glaukos is supported by strong underlying demand in iDose, where survey work shows high-volume SLT/DSLT physicians averaging 220 procedures in 2024 and expected to reach 290 in 2026, while repeat respondents raised 2026 volume expectations more often than they lowered them. The company also appears well positioned to benefit from expanding iDose utilization in combination with MIGS, with the mix expected to rise to 54%/65% in 2027, and even under conservative LCD assumptions, projected iDose sales remain robust at about $300M/$385M in 2027/2028. Beyond iDose, the bullish case is reinforced by Epioxa, which is emerging as a second growth engine with potential to drive a 2027-2028 top-line acceleration and offset reimbursement-related pressure.

Bear case

Glaukos is facing a fundamentally challenged growth setup because its iDose TR launch is exposed to potentially prohibitive LCD restrictions, including fail-first requirements and limits on combining MIGS, which physicians say would delay care and make patient access harder. Survey data cited in the paragraphs points to a roughly -25% impact to iDose volumes if the draft LCDs are finalized as proposed, with Street estimates for CY27 potentially needing to come down about 10%, while roughly 47% of iDose procedures already involved prior SLT/DSLT and 26% were done with MIGS. At the same time, the company’s corneal business is under pressure as Photrexa is no longer being made, inventories are dwindling, and some physicians are not converting to Epioxa, leaving Glaukos with reimbursement risk, slower adoption, and weaker product momentum across key franchises.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.